Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study-Reference-Cited by-同舟云学术

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

Published:2020-03-30 Issue:3 Volume:26 Page:494-502
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Nolan Beatrice¹^ORCID,Mahlangu Johnny²^ORCID,Pabinger Ingrid³,Young Guy⁴⁵^ORCID,Konkle Barbara A.⁶^ORCID,Barnes Chris⁷,Nogami Keiji⁸^ORCID,Santagostino Elena⁹,Pasi K. John¹⁰^ORCID,Khoo Liane¹¹,Winding Bent¹²,Yuan Huixing¹³,Fruebis Joachim¹⁴,Rudin Dan¹⁴,Oldenburg Johannes¹⁵^ORCID

Affiliation:

1. Children's Health Ireland at Crumlin Dublin Ireland

2. Haemophilia Comprehensive Care Centre Faculty of Health Sciences Charlotte Maxeke Johannesburg Academic Hospital and NHLS University of Witwatersrand Johannesburg South Africa

3. Medizinische Universität Wien Vienna Austria

4. Children’s Hospital Los Angeles Los Angeles CA USA

5. University of Southern California Keck School of Medicine Los Angeles CA USA

6. Bloodworks Northwest Seattle WA USA

7. The Royal Children’s Hospital Parkville Vic. Australia

8. Nara Medical University Kashiwara Japan

9. Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico Milan Italy

10. Royal London Haemophilia Centre Barts and The London School of Medicine and Dentistry London UK

11. Royal Prince Alfred Hospital Camperdown NSW Australia

12. Sobi Stockholm Sweden

13. Sanofi Cambridge MA USA

14. Bioverativ, a Sanofi company Waltham MA USA

15. Institute of Experimental Haematology and Transfusion Medicine University Clinic Bonn Bonn Germany

Funder

Sanofi

Swedish Orphan Biovitrum

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13953

Reference29 articles.

1. National Hemophilia Foundation.MASAC document 241: MASAC recommendations concerning Prophylaxis.https://www.hemophilia.org/Researchers‐Healthcare‐Providers/Medical‐and‐Scientific‐Advisory‐Council‐MASAC/MASAC‐Recommendations/MASAC‐Recommendation‐Concerning‐Prophylaxis. Accessed October 25 2018.

2. Individualizing prophylaxis in hemophilia: a review

3. Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?

5. Hemophilia A in the third millennium

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term clinical outcomes of prophylaxis with an rFVIIIFc or rFIXFc in adults aged ≥50 years with hemophilia A or B;Blood Advances;2024-09-24

2. Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany;Research and Practice in Thrombosis and Haemostasis;2024-07

3. Changes in Quality of Life, Adherence, and Kinesiophobia in Patients with Hemophilia Treated with Extended Half-Life Treatment: Final Results of the LongHest Project;Pharmaceuticals;2024-06-25

4. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors;Advances in Therapy;2024-04-23

5. Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII;Acta Haematologica;2024-04-23